<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32052165</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Prognostic role of slow vital capacity in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1615</StartPage><EndPage>1621</EndPage><MedlinePgn>1615-1621</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09751-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To compare the prognostic role of FVC and SVC at diagnosis in amyotrophic lateral sclerosis (ALS) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all patients from the Piemonte and Valle D'Aosta ALS register (PARALS) who had been diagnosed with ALS between 1995 and 2015 and underwent spirometry at diagnosis. Survival was considered as time to death/tracheostomy; to assess the prognostic value in typical trial timeframes, survival at 12 and 18&#xa0;months was calculated too. Cox proportional hazard regression models adjusted by sex, age at diagnosis, diagnostic delay, onset site, and ALSFRS-R total score at the moment of diagnosis were used to assess the prognostic role of FVC and SVC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 795 ALS patients underwent spirometry at diagnosis during the study period. Four hundred and sixteen (52.3%) performed both FVC and SVC, whereas the others performed FVC only. FVC and SVC values were highly correlated (r&#x2009;=&#x2009;0.92, p&#x2009;&lt;&#x2009;0.001) in the overall population and slightly less correlated in patients with bulbar onset (r&#x2009;=&#x2009;0.86, p&#x2009;&lt;&#x2009;0.001). Both FVC and SVC proved to have a prognostic role with comparable hazard ratios (HRs) (HR 1.83, 95% CI 1.48-2.27 and 1.88, 95% CI 1.51-2.33, respectively). When considering typical trial timeframes, HRs remained similar and were inversely proportional to FVC and SVC values.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">FVC and SVC at diagnosis can be used interchangeably as independent predictors of survival in both clinical and research settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy. andrea.calvo@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteoni</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattei</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>SC Pneumologia, AOU Citt&#xe0; della Salute e della Scienza of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Mancusa</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Focaraccio</LastName><ForeName>Luana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Presidio ASL4, Pneumologia, Turin, Lanzo Torinese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center, Ospedale Maggiore della Carit&#xe0;, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>D'Ovidio</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center, "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 1026, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013147" MajorTopicYN="N">Spirometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cohort studies</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Slow vital capacity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32052165</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09751-1</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09751-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084&#x2013;2098. https://doi.org/10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotrophic Lateral Sclerosis (ALS) Fact Sheet|National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet . Accessed 20 Mar 2019</Citation></Reference><Reference><Citation>Pinto S, de Carvalho M (2015) The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Front Degener 16:120&#x2013;123. https://doi.org/10.3109/21678421.2014.952641</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.952641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Lacomblez L, Abitbol JL et al (2014) A phase II&#x2013;III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 21:529&#x2013;536. https://doi.org/10.1111/ene.12344</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH (2006) Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 77:390&#x2013;392. https://doi.org/10.1136/jnnp.2005.072660</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId><ArticleId IdType="pmc">2077717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilanus TBM, Groothuis JT, TenBroek-Pastoor JMC et al (2017) The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis. Respir Res 18:144. https://doi.org/10.1186/s12931-017-0624-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-017-0624-8</ArticleId><ArticleId IdType="pubmed">28743265</ArticleId><ArticleId IdType="pmc">5526316</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, De Carvalho M (2015) Sessions 1&#x2013;11. Amyotroph Lateral Scler Front Degener 16:1&#x2013;62. https://doi.org/10.3109/21678421.2015.1089039</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1089039</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Beck M, Giess R et al (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709&#x2013;714. https://doi.org/10.1002/mus.10090</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF et al (2018) Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol 75:58&#x2013;64. https://doi.org/10.1001/jamaneurol.2017.3339</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3339</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Verma R, Garg RK et al (2011) Assessment of respiratory functions by spirometry and phrenic nerve studies in patients of amyotrophic lateral sclerosis. J Neurol Sci 306:76&#x2013;81. https://doi.org/10.1016/j.jns.2011.03.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.03.039</ArticleId><ArticleId IdType="pubmed">21496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyall RA, Donaldson N, Polkey MI et al (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain J Neurol 124:2000&#x2013;2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/124.10.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C, De Carvalho M, Genge A et al (2018) Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotroph Lateral Scler Front Degener. https://doi.org/10.1080/21678421.2018.1497658</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497658</ArticleId></ArticleIdList></Reference><Reference><Citation>Enache I, Pistea C, Fleury M et al (2017) Ability of pulmonary function decline to predict death in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Front Degener 18:511&#x2013;518. https://doi.org/10.1080/21678421.2017.1353097</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353097</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Henderson RD, Morrison SC et al (2010) Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:194&#x2013;202. https://doi.org/10.3109/17482960902991773</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902991773</ArticleId><ArticleId IdType="pubmed">19452343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2017) Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Front Degener 18:86&#x2013;91. https://doi.org/10.1080/21678421.2016.1249486</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1249486</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Zhang H, Shefner JM et al (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933&#x2013;1935</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000144345.49510.4E</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JLP et al (2005) The ALSFRSr predicts survival time in an ALS clinic population. Neurology 64:38&#x2013;43. https://doi.org/10.1212/01.WNL.0000148648.38313.64</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2019) SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol 10:109. https://doi.org/10.3389/fneur.2019.00109</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00109</ArticleId><ArticleId IdType="pubmed">30873101</ArticleId><ArticleId IdType="pmc">6403463</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2017) Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Front Degener 18:528&#x2013;533. https://doi.org/10.1080/21678421.2017.1354995</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1354995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Moglia C et al (2017) Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d&#x2019;Aosta Register. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2017.1387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1387</ArticleId><ArticleId IdType="pubmed">28692730</ArticleId><ArticleId IdType="pmc">7112760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Manera U, Calvo A, Daviddi M et al (2019) Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2019-321153</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321153</ArticleId><ArticleId IdType="pubmed">31871138</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis, and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2014;revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;375. https://doi.org/10.1111/j.1468-1331.2011.03501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Polkey MI, Green M, Moxham J (1995) Measurement of respiratory muscle strength. Thorax 50:1131&#x2013;1135</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.50.11.1131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Wiener CM, Shade DM et al (2002) Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 121:436&#x2013;442</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.121.2.436</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso P, de Albuquerque ALP, Santana PV et al (2015) Diagnostic methods to assess inspiratory and expiratory muscle strength. J Bras Pneumol 41:110&#x2013;123. https://doi.org/10.1590/S1806-37132015000004474</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1806-37132015000004474</ArticleId><ArticleId IdType="pubmed">25972965</ArticleId><ArticleId IdType="pmc">4428848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Rosenfeld J, Moore DH et al (2001) A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 191:75&#x2013;78</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00617-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitting JW, Paillex R, Hirt L et al (1999) Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 46:887&#x2013;893</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;887::AID-ANA11&gt;3.0.CO;2-L</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2018) Sniff nasal inspiratory pressure (SNIP) in amyotrophic lateral sclerosis: relevance of the methodology for respiratory function evaluation. Clin Neurol Neurosurg 171:42&#x2013;45. https://doi.org/10.1016/j.clineuro.2018.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2018.05.011</ArticleId><ArticleId IdType="pubmed">29807198</ArticleId></ArticleIdList></Reference><Reference><Citation>Capozzo R, Quaranta VN, Pellegrini F et al (2015) Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol 262:593&#x2013;603. https://doi.org/10.1007/s00415-014-7613-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7613-3</ArticleId><ArticleId IdType="pubmed">25522696</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan RK, McNally S, Alexander M et al (2005) Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 171:269&#x2013;274. https://doi.org/10.1164/rccm.200403-314OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200403-314OC</ArticleId><ArticleId IdType="pubmed">15516537</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda C, Shimizu T, Nakayama Y, Haraguchi M (2019) Cough peak flow decline rate predicts survival in patients with amyotrophic lateral sclerosis. Muscle Nerve 59:168&#x2013;173. https://doi.org/10.1002/mus.26320</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26320</ArticleId><ArticleId IdType="pubmed">30106482</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Pinto A, de Carvalho M (2012) Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol 123:2454&#x2013;2459. https://doi.org/10.1016/j.clinph.2012.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.05.012</ArticleId><ArticleId IdType="pubmed">22762911</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M, Glatz C, Helmle C et al (2018) Prevalence of sleep apnoea and capnographic detection of nocturnal hypoventilation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89:418&#x2013;424. https://doi.org/10.1136/jnnp-2017-316515</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316515</ArticleId><ArticleId IdType="pubmed">29054915</ArticleId><ArticleId IdType="pmc">29054915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Bradburn M, Proctor AR et al (2012) Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: a validation study. Amyotroph Lateral Scler 13:528&#x2013;532. https://doi.org/10.3109/17482968.2012.688836</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.688836</ArticleId><ArticleId IdType="pubmed">22871078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman PL, Belsh JM (1993) Pulmonary function at diagnosis of amyotrophic lateral sclerosis: rate of deterioration. Chest 103:508&#x2013;513</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.103.2.508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Canosa A, Gallo S et al (2011) ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology 77:1432&#x2013;1437. https://doi.org/10.1212/WNL.0b013e318232ab9b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318232ab9b</ArticleId><ArticleId IdType="pubmed">21956723</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Westeneng H-J, Nikolakopoulos S et al (2019) Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. https://doi.org/10.1212/WNL.0000000000006855</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pubmed">32042914</ArticleId><ArticleId IdType="pmc">6369899</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>